Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Director | May 28, 2020 | June 01, 2020 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | May 24, 2024 | May 29, 2024 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 15, 2026 | May 16, 2026 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERCEPT PHARMACEUTICALS, INC.
Report date May 28, 2020 · Filed June 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,060 |
Reported balance
After 2020-05-28 transaction · row 1
1 source rowRow 1 · 2020-05-28 · Grant · Acquired 1,595 · Balance 8,060 F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 · Expires 2030-05-28 | Direct | 2,966 |
Reported balance
After 2020-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-28 · Grant · Acquired 2,966 · Balance 2,966 F2: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders.
F2: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders.
Nuvation Bio Inc.
Report date May 24, 2024 · Filed May 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 659,947 |
Ending reported balance
After 2024-05-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-24 · Exercise / conversion · Acquired 293,203 · Balance 293,203 Row 2 · 2024-05-24 · Exercise / conversion · Acquired 366,744 · Balance 659,947 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-07-21 | Direct | 19,547 |
Reported balance
After 2024-05-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-24 · Exercise / conversion · Disposed 293,203 · Balance 19,547 F1: Option vests in 48 equal monthly installments from July 22, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2033-05-14 | Direct | 0 |
Reported balance
After 2024-05-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-24 · Exercise / conversion · Disposed 366,744 · Balance 0 F2: Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 48 equal monthly installments from July 22, 2020.
F2: Option is fully vested and exercisable.
PROTHENA CORP PUBLIC LTD CO
Report date May 15, 2026 · Filed May 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2036-05-15 | Direct | 27,000 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,441 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 40,441 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Acquired 1,106 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 35,552 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 4,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 10,725 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2023 Filed Mar 16, 2023 06:05 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 283 | $202.36 | $57,267.88 |
DisclosureSEC source: 0000899243-23-008695 · doc4.xml · nonDerivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,407 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $202.12 to $202.47. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| March 13, 2023 Filed Mar 16, 2023 06:05 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 283 | $39.94 | $11,303.02 |
DisclosureSEC source: 0000899243-23-008695 · doc4.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| March 13, 2023 Filed Mar 16, 2023 06:05 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,758 | $38.82 | $223,525.56 |
DisclosureSEC source: 0000899243-23-008695 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:12 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries B Preferred Shares · Derivative | 123,508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-008168 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Ordinary Shares · 123,508 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F1 · price: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F1 · derivative.exercise_date: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F1 · derivative.expiration_date: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:12 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 123,508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-008168 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 123,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 17:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,245 | $0.00 Strike: $60.57 | $0.00 |
DisclosureSEC source: 0001209191-22-039568 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 6,245 shares Expires 2032-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 17:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039568 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,745 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:51 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 118,784 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-22-030085 · doc4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,784 Underlying: Class A Common Stock · 118,784 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| May 16, 2022 Filed Jun 28, 2022 23:11 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 140,713 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-22-039680 · doc4a.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,713 Underlying: Class A Common Stock · 140,713 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| May 13, 2022 Filed May 17, 2022 19:28 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,676 | $0.00 Strike: $135.63 | $0.00 |
DisclosureSEC source: 0000899243-22-018459 · doc4.xml · derivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,676 Underlying: Common Stock · 3,676 shares Expires 2032-05-13 Read SEC document |
| May 13, 2022 Filed May 17, 2022 19:28 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018459 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,649 F1 · kind: These restricted stock units will be settled in common stock upon vesting. F2 · shares: These restricted stock units shall vest in full on May 13, 2023. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 01:31 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 45,229 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001209191-21-062588 · doc4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,229 Underlying: Class A Common Stock · 45,229 shares Expires 2031-10-28 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (October 29, 2022); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:27 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $93.20 | $0.00 |
DisclosureSEC source: 0001209191-21-043549 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Stock · 4,125 shares Expires 2031-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:27 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043549 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,445 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 09, 2021 Filed Feb 11, 2022 17:19 UTC | Seagen Inc. SGEN · Entity 13956 | GiftCommon Stock | 33,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005850 · doc5.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 33,785 F1 · kind: On June 9, 2021, the reporting person transferred 33,785 shares of common stock to an irrevocable trust of which the reporting person's spouse is the trustee. Members of the reporting person's family are the sole beneficiaries of the trust. F1 · ownership.nature: On June 9, 2021, the reporting person transferred 33,785 shares of common stock to an irrevocable trust of which the reporting person's spouse is the trustee. Members of the reporting person's family are the sole beneficiaries of the trust. Read SEC document |
| June 09, 2021 Filed Feb 11, 2022 17:19 UTC | Seagen Inc. SGEN · Entity 13956 | GiftCommon Stock | 33,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005850 · doc5.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,146 F1 · kind: On June 9, 2021, the reporting person transferred 33,785 shares of common stock to an irrevocable trust of which the reporting person's spouse is the trustee. Members of the reporting person's family are the sole beneficiaries of the trust. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 14, 2021 Filed May 18, 2021 19:22 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,462 | $0.00 Strike: $147.50 | $0.00 |
DisclosureSEC source: 0001203311-21-000030 · edgardoc.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,462 Underlying: Common Stock · 3,462 shares Expires 2031-05-14 Read SEC document |
| May 14, 2021 Filed May 18, 2021 19:22 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-21-000030 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,931 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 14, 2022. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:51 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 312,750 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010347 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,750 Underlying: Class A Common Stock · 312,750 shares Expires 2030-07-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 312,307 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest in 48 equal monthly installments from July 22, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:51 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 86,184 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010347 · doc4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,184 Underlying: Class A Common Stock · 86,184 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 86,603 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,750 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · derivative · entry 16 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2023-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Options were fully vested on 5/16/14. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,750 | $0.00 Strike: $34.25 | $0.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · derivative · entry 15 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2024-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Options were fully vested on 5/15/15. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,518 | $0.00 Strike: $20.06 | $0.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · derivative · entry 14 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,518 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,982 | $0.00 Strike: $20.06 | $0.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · derivative · entry 13 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,518 Underlying: Common Stock · 7,982 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Options were fully vested on 5/17/13. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,500 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · derivative · entry 12 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,500 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options were fully vested on 5/20/12. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 9,250 | $164.61 | $1,522,642.50 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 11 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,348 F7 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $164.49 to $164.72. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 14,500 | $165.06 | $2,393,370.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 10 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,598 F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $164.72 to $165.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 14,500 | $19.02 | $275,790.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 9 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 9,518 | $165.72 | $1,577,322.96 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 8 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,598 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $165.31 to $166.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 9,518 | $20.06 | $190,931.08 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 7 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 7,982 | $166.70 | $1,330,599.40 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 6 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,598 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $166.33 to $166.98. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 7,982 | $20.06 | $160,118.92 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 5 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 8,750 | $167.34 | $1,464,225.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 4 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,598 F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $166.98 to $167.91. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 8,750 | $36.70 | $321,125.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 8,750 | $168.24 | $1,472,100.00 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,598 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $167.91 to $168.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:51 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 8,750 | $34.25 | $299,687.50 |
DisclosureSEC source: 0001203311-20-000120 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 02, 2020 Filed Feb 5, 2021 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | GiftCommon Stock | 6,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-21-000009 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,529 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 17:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $76.58 | $0.00 |
DisclosureSEC source: 0001209191-20-039410 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2030-06-26 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 17:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039410 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021 Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,966 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0001104659-20-068530 · tm2021501d2_4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966 Underlying: Common Stock · 2,966 shares Expires 2030-05-28 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-068530 · tm2021501d2_4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,060 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 15, 2020 Filed May 19, 2020 19:11 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,171 | $0.00 Strike: $160.33 | $0.00 |
DisclosureSEC source: 0001203311-20-000052 · edgardoc.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,171 Underlying: Common Stock · 3,171 shares Expires 2030-05-15 Read SEC document |
| May 15, 2020 Filed May 19, 2020 19:11 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-20-000052 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,598 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 15, 2021. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 06, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 205 | $166.77 | $34,187.85 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 8 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,263 F8 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $166.70 to $166.83. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F9 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 06, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 2,435 | $166.23 | $404,770.05 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 7 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,468 F7 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $165.66 to $166.64. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 06, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,319 | $164.98 | $712,548.62 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 6 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,903 F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $164.64 to $165.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 06, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 8,041 | $164.21 | $1,320,412.61 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 5 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,222 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $163.64 to $164.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 284 | $167.99 | $47,709.16 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 4 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,263 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $167.92 to $168.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 11,011 | $167.26 | $1,841,699.86 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,547 F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $166.92 to $167.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:59 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,400 | $166.27 | $897,858.00 |
DisclosureSEC source: 0001203311-20-000028 · edgardoc.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,558 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $165.89 to $166.88. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.